Ludwig Institute for Cancer Research Limited

Other

Memorial Sloan Kettering Cancer Center

Cornell University

The New York Hospital-cornell Medical Center

Abbott Laboratories Corporation

Ludwig Institute of Cancer Research

Elisabeth Stockert

Lloyd J Old

Yao-tseng Chen

Matthew J Scanlan

Ali O Gure

Pilar Garin-Chesa

Alexander Knuth

Elke Jager

Elke J&auml;ger

Wolfgang J Rettig

Dirk Jager

Knuth Alexander

Francis Joseph Carr

Sydney Welt

Lloyd Old

Achim Jungbluth

Kathryn Lesley Armour

Kunio Kitamura

Solam Tsang

Gerd J Ritter

Webster K Cavenee

Yachi Chen

Maria P Sanz-Moncasi

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Con Panousis

Antony Wilks Burgess

Ivan Tarasovich Gout

Thomas Paul Wallace

Christoph Renner

Edouard Collins Nice

Terrance Grant Johns

Elke Jäger

Cynthia H Scanlan, Legal Representative

Andrew Mark Scott

Barry C Picker, Legal Representative

Huei-Jen Su Huang

Yao-Tseng Chen

Peter Collins

Alex Knuth

Huei-Jen Huang

Anthony Wilks Burgess

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Specific binding proteins and uses thereof

The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof

The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers for diagnosing breast cancer, and for following the course of treatment of breast cancer.

Breast cancer antigens

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with small cell lung cancer. The invention provides, among other things, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

Small cell lung cancer associated antigens and uses therefor

The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.

Isolated nucleic acid molecules encoding ESO-1 peptides and uses thereof

Various molecules associated with disorders such as cancer are disclosed. The invention also discloses diagnostic aid therapeutic methods based upon these molecules, as well as compositions for stimulating an immune response and methods for identifying cancer-associated nucleic acid and polypeptide molecules.

Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer

The invention relates to newly identified cancer associated antigens, referred to as CT7, KOC-2 and KOC-3. The invention also relates to observations regarding known molecule KOC-1. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

Isolated nucleic acid molecule encoding cancer associated antigens, the antigens per se, and uses thereof

The invention provides methods for diagnosing cancer including colon cancer, based on the identification of certain colon cancer-associated polypeptides as antigens that elicit immune responses in colon cancer. The identified antigens can be utilized as markers for diagnosing colon cancer, and for following the course of treatment of colon cancer.

Colon cancer antigen panel

The invention relates to the isolation of a nucleic acid molecule which encodes a cancer associated antigen. Also a part of the invention is the antigen itself, and the uses of the nucleic acid molecule and the antigen, and peptides derived from it.

Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof

Truncated forms of NY-ESO-1 protein

Various molecules associated with disorders such as cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules, as well as compositions for stimulating an immune response and methods for identifying cancer-associated nucleic acid and polypeptide molecules.

The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by the murine antibody Lewis Y. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumor types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumors. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.

Recombinant human anti-Lewis Y antibodies

Growing community of inventors

New York, NY, United States of America

Elisabeth Stockert